PepGen has shared positive initial data from its ongoing FREEDOM-DM1 Phase I trial, which is evaluating PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1). In the 5mg/kg and 10mg/kg dose ...
Rentosertib, an AI-discovered TNIK inhibitor, showed safety and tolerability in a phase 2a trial for idiopathic pulmonary fibrosis. The trial involved 71 patients, with similar adverse event rates ...
Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer Data from first ...
Ferring Pharmaceuticals presented the first results from an ongoing Phase 3 trial in Japan assessing the efficacy and safety of nadofaragene firadenovec in patients with high-risk Bacillus ...
Immunocore reports positive initial data for HIV treatment candidate IMC-M113V, showing safety and signs of viral control post-treatment. The observation of delayed viral rebound and/or viremia ...
A Phase 1b clinical trial testing pociredir in adults with sickle cell disease has completed enrollment of its high-dose ...
NEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on chromosomal instability, today announced preliminary safety and efficacy data from its ...
Clinical Trials Arena on MSN
Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint
According to the company, this study is the third positive trial for Gazyva/Gazyvaro for treating immune-mediated conditions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback